Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.000
Sell
RSI(14)
45.744
Neutral
STOCH(KDJ)(9,3,3)
60.257
Neutral
ATR(14)
2.299
High Vlolatility
CCI(14)
-17.640
Neutral
Williams %R
56.990
Sell
TRIX(12,20)
-0.172
Sell
StochRSI(14)
29.901
Sell
Search
ANI Pharmaceuticals Inc
ANIPAdd to Watchlist
79.240USD
-1.190-1.48%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.80BMarket Cap
19.26P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.48%
5 Days
+2.05%
1 Month
-4.59%
6 Months
-0.95%
Year to Date
+0.38%
1 Year
+23.95%
Key Figures
79.650Open
80.380High
205.18KVolume
19.26P/E TTM
7.42P/E Dynamic
--Dividend TTM
0.91%Turnover Ratio
80.430Prev. Close
78.240Low
13.56MTurnover
LossP/E Static
3.52P/B
0.00%Div Yield TTM
6.79%ROA
99.50052wk High
0.82Volume Ratio
-20.15MNet Profit
22.47MShares
4.1138EPS TTM
0.45Beta
17.11%ROE
57.33052wk Low
2.66%Amplitude
51.78%Gross Margin
1.80BMarket Cap
-2.77Reward/Risk
1.96%Risk Rate
TradingKey Stock Score of ANI Pharmaceuticals Inc
Currency: USD Updated: 2026-07-31Key Insights
ANI Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 10 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 109.29.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ANI Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
ANI Pharmaceuticals Inc Highlights
StrengthsRisks
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 81.46% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 883.37M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 19.26, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 23.15M shares, increasing 0.25% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 49.41K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
109.286
Target Price
+37.92%
Upside Space
ANI Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
8
analysts
Buy
Current Rating
109.286
Target Price
+37.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
ANI Pharmaceuticals Inc
ANIP
8
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
80.172
Sell
MA10
79.152
Buy
MA20
80.837
Sell
MA50
81.115
Sell
MA100
79.439
Sell
MA200
81.244
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ANI Pharmaceuticals Inc Info
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Ticker SymbolANIP
CompanyANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
Websitehttps://www.anipharmaceuticals.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52668.200
+290.200 (+0.55%)
28466.100
+305.200 (+1.08%)
7521.200
+46.100 (+0.62%)
14790.000
+41.000 (+0.28%)
63736.000
+884.000 (+1.41%)
6392.500
+27.100 (+0.43%)
79.932
-6.002 (-6.98%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4070.480
+29.050 (+0.72%)
FAQs
What is the current price of ANI Pharmaceuticals Inc (ANIP)?
The current price of ANI Pharmaceuticals Inc (ANIP) is 79.24.
What is the symbol of ANI Pharmaceuticals Inc?
The ticker symbol of ANI Pharmaceuticals Inc is ANIP.
What is the 52-week high of ANI Pharmaceuticals Inc?
The 52-week high of ANI Pharmaceuticals Inc is 99.50.
What is the 52-week low of ANI Pharmaceuticals Inc?
The 52-week low of ANI Pharmaceuticals Inc is 57.33.
What is the market capitalization of ANI Pharmaceuticals Inc?
The market capitalization of ANI Pharmaceuticals Inc is 1.78B.
Is ANI Pharmaceuticals Inc (ANIP) currently rated as Buy, Hold, or Sell?
According to analysts, ANI Pharmaceuticals Inc (ANIP) has an overall rating of Buy, with a price target of 109.29.
What is the Earnings Per Share (EPS TTM) of ANI Pharmaceuticals Inc (ANIP)?
The Earnings Per Share (EPS TTM) of ANI Pharmaceuticals Inc (ANIP) is 3.50.